Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

XDx and Bristol-Myers Squibb Enter into Pharmacogenomics Collaboration

By Pharmaceutical Processing | January 9, 2009

XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, announced today that it has signed a collaborative pharmacogenomics agreement with Bristol-Myers Squibb Company. The collaboration is focused on identifying biomarkers in the field of Systemic Lupus Erythematosus (SLE) for clinical diagnostic purposes associated with the clinical development of Orencia® (abatacept), a Bristol-Myers Squibb drug approved for the treatment of rheumatoid arthritis. Bristol-Myers Squibb will make an upfront payment to XDx in addition to milestone payments upon the successful achievement of specific research and development objectives. XDx will receive commercial rights to certain diagnostic applications resulting from the collaboration. “This collaborative agreement with Bristol-Myers Squibb further underscores our leadership in gene expression technologies and analysis applied to molecular diagnostics and demonstrates our ongoing commitment to patients battling serious immune-mediated disorders such as lupus,” said Pierre Cassigneul, president and chief executive officer, XDx. “We are pleased to be working with our new partners at Bristol-Myers Squibb and we intend to continue leveraging our R&D, clinical, and bioinformatics capabilities through partnerships to further demonstrate the utility of our innovative biomarker identification technologies and diagnostic work in autoimmune disease.”

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE